Media stories about Collegium Pharmaceutical (NASDAQ:COLL) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a news impact score of 0.20 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 48.691940105105 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up 2.13% during midday trading on Friday, hitting $9.60. 292,792 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $11.49 and its 200 day moving average price is $11.56. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.55. The firm’s market cap is $283.83 million.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. Equities research analysts forecast that Collegium Pharmaceutical will post ($3.00) EPS for the current year.

A number of brokerages have commented on COLL. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, June 9th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $25.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, June 12th. Piper Jaffray Companies set a $14.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, July 25th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $22.00 target price (down from $24.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $21.33.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/25/collegium-pharmaceutical-coll-given-news-sentiment-score-of-0-20.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.